The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Medivation

  • MDVN
  • NASDAQ
  • Consumer Products
  • Latest 74.865
  • Currency US$
  • Change -0.945
  • Percent Change -1.247 %
  • Volume 515,390
  • Fri Jul 11, 2014 01:16 PM EDT NASDAQ data delayed 15 minutes.
  • Open 75.23
  • Previous Close 75.81
  • High 75.421
  • Low 73.72
  • Bidx2 74.85
  • Askx1 74.89
  • 52-week High02/25 88.199
  • 52-week Low10/22 48.15
  • Beta 4.20
  • Market Cap 5,714.45M
  • EPS -0.40
  • P/E
  • Forward P/E 25.87
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $313,980,000
  • Earnings $-29,100,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $241,460,000
  • Current Ratio 3.87

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $398,060,000
  • Liabilities $316,100,000
  • Liabilities-to-Equity Ratio 3.86

Price Ratios

  • Price to Sales 18.18
  • Price to Book 69.63
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 8 $-0.03 Aug 14 $0.27
Surprises May 8 500.00% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 11, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices

Related Securities
Symbol Type Latest % Chg

Officers

  • David T. Hung, M.D. President; C.E.O. & Director
  • C. Patrick Machado Chief Business Officer & C.F.O
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

525 MARKET STREET 36TH FLOOR
SAN FRANCISCO, CA
94105

Phone: (415)-543-3470
Fax: (415)-5433411

investors@medivation.com
www.medivation.com

Ideas & Discussion

Live Discussion of MDVN on StockTwits